Axim Biotechnologies Inc
OTCQB:AXIM

  • LAST PRICE
    0.0137
  • TODAY'S CHANGE (%)
    0.0015 (11.8367%)
  • Bid / Lots
    ---/ ---
  • Ask / Lots
    ---/ ---
  • Open / Previous Close
    0.0133 / 0.0123
  • Day Range
    0.0124
    0.0149
  • 52 Week Range
    0.0090
    0.0399
  • Volume
    126,525

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Mar 27, 2024

      Show headlines and story abstract

    • 9:01AM ET on Wednesday Mar 27, 2024 by Dow Jones
      Companies Mentioned: AXIM

      VIDEO: AXIM Biotechnologies CEO Presents at Benzinga Virtual Healthcare Summit 2024

      Company CEO John Huemoeller II Interviewed by Tony Noto on AXIM's Diagnostic Research Programs in Dry Eye Disease and Parkinson's

    • 9:00AM ET on Wednesday Mar 27, 2024 by GlobeNewswire
      Companies Mentioned: AXIM

    • 9:00AM ET on Wednesday Mar 27, 2024 by Dow Jones
      Companies Mentioned: AXIM

      Company CEO John Huemoeller II Interviewed by Tony Noto on AXIM's Diagnostic Research Programs in Dry Eye Disease and Parkinson's

      SAN DIEGO, CA, March 27, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire https://www.globenewswire.com/Tracker?data=0v63TFQI2MJ5wbw1LM5kg9Ws7RTR7vfcIWzL7VZNEQCDXvHCPNFfnsutXBasUWCiR4g_ITQLndEmoYmk21DNsXOl4pv_b3g5VUzQjgrfb3s= --AXIM Biotechnologies, Inc https://www.globenewswire.com/Tracker?data=ZV9ZmJKeJ8sDwibY7brKjFpJ5JG9BUqioksMOhK-gIw4kChnTNKTkAilFZl4Ayatu8J-vT2GO9TGjOJNOxsPXwIS0_L7yMVrXnZ7VUGMRJ_r4O-mVd9sokf_haoO7vKa6i7-1tgcwyM4DYoXdVa6d6bPKJD-qqE-JXrYRTkdNYTSNmIHi3GvM1XEbApmPhlKbjIXgK8c1ty5jja5N0GXJ0RyhL0_ZvtZpIL9MFxo2HPD_4Kr6AwN-TWwxlDjpFkDk9PQ5vBGr94Qh-wV2pJNZw== . (OTCQB: AXIM https://www.globenewswire.com/Tracker?data=fw_0FtNb8Z4qAaxMw_dahGO93ECYLs49CfZgYyv22Izv9D57c4Vk61uqUIupNV_XDf6CCNYBzqYifbI95Nihot4vmuaabDKj7ax036OpDPKsFLPxlQkWmhjH8TRd_Dic4ZZ4phVAQiogQFiu5SWdt0EJ3Xtgv8bgissXA08Qyb4Lc0Jqf8A4eLkDi3UN6bOH5MqiQDOfkp6u51L6d3uQvHPZn0fGdAYcmzx9MtMarvdLZDbXXBIkenhNIib2T4Wb ) ("AXIM Biotech," "AXIM" or "the Company"), an international healthcare diagnostic solutions development company, today released a fireside chat interview conducted with its CEO John Huemoeller II and Tony Noto at the 2024 Benzinga Virtual Healthcare Summit https://www.globenewswire.com/Tracker?data=eEwd9NG2M5lkJGuikMtCZPyTSMYeiUgx_qgOjz7dD4T9lEyKget-AZLqBn-Qly8lsiRZ-2gsyscfubOyA4tgfB4lOdS_LhOqBajBcCzwkRcKPwH423wpdcv2QTvuBsoM3QG_F2sIagqEqpbv7COL7kopffHpEEJbwIJueRNNRuI= . During the presentation, Mr. Huemoeller shares insights into the Company's work with its two FDA-cleared ophthalmological diagnostic assays currently being marketed to clinicians throughout the country as well as research being conducted in its Parkinson's diagnostic program.

Peers Headlines